{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:05:09Z","timestamp":1778627109658,"version":"3.51.4"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,26]]},"DOI":"10.7759\/cureus.78018","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T01:53:31Z","timestamp":1737942811000},"source":"Crossref","is-referenced-by-count":1,"title":["Primary Sjogren\u2019s Disease Coexisting With Myasthenia Gravis: Two Distinct Autoimmune Diseases Successfully Treated With a Rituximab-Based Induction Regimen"],"prefix":"10.7759","author":[{"given":"Abraham","family":"Mohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijo","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiswarya","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sojan K","family":"Scaria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Sj\u00f6gren's syndrome: a case study","volume":"7","author":"Jadhav S","year":"2015","unstructured":"Jadhav S, Jadhav A, Thopte S, Marathe S, Vhathakar P, Chivte P, Jamkhande A. Sj\u00f6gren's syndrome: a case study. J Int Oral Health. 2015, 7:72-4.","journal-title":"J Int Oral Health"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.fdj.2016.10.001","article-title":"Sj\u00f6gren\u2019s syndrome in a 25-year-old female: a case study","volume":"2","author":"Khalele BA","year":"2016","unstructured":"Khalele BA. Sj\u00f6gren\u2019s syndrome in a 25-year-old female: a case study. Future Dent J. 2016, 2:94-8. 10.1016\/j.fdj.2016.10.001","journal-title":"Future Dent J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60327-957-4","article-title":"Sj\u00f6gren\u2019s Syndrome: Practical Guidelines to Diagnosis and Therapy","author":"Fox RI","year":"2016","unstructured":"Fox RI, Fox CM. Sj\u00f6gren\u2019s Syndrome: Practical Guidelines to Diagnosis and Therapy. Springer, New York, NY; 2016. 10.1007\/978-1-60327-957-4"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00939","article-title":"Myasthenia gravis coexisting with primary Sj\u00f6gren's syndrome: report of three cases and literature review","volume":"11","author":"Li X","year":"2020","unstructured":"Li X, Zhao Y, Liao Q, Da Y. Myasthenia gravis coexisting with primary Sj\u00f6gren's syndrome: report of three cases and literature review. Front Neurol. 2020, 11:939. 10.3389\/fneur.2020.00939","journal-title":"Front Neurol"},{"key":"ref5","article-title":"Myasthenia gravis","author":"Suresh AB","year":"2023","unstructured":"Suresh AB, Asuncion RM. Myasthenia gravis. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders DB","year":"2010","unstructured":"Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity. 2010, 43:428-35. 10.3109\/08916930903518107","journal-title":"Autoimmunity"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina D","year":"2022","unstructured":"S\u00e1nchez-Tejerina D, Sotoca J, Llaurado A, L\u00f3pez-Diego V, Juntas-Morales R, Salvado M. New targeted agents in myasthenia gravis and future therapeutic strategies. J Clin Med. 2022, 11:6394. 10.3390\/jcm11216394","journal-title":"J Clin Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2015.01.002","article-title":"Myasthenia gravis presenting as persistent unilateral ptosis with facial droop","volume":"49","author":"Golden SK","year":"2015","unstructured":"Golden SK, Reiff CJ, Painter CJ, Repplinger MD. Myasthenia gravis presenting as persistent unilateral ptosis with facial droop. J Emerg Med. 2015, 49:e23-5. 10.1016\/j.jemermed.2015.01.002","journal-title":"J Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2016.03.002","article-title":"Autoantibodies in Sj\u00f6gren's syndrome","volume":"42","author":"Fayyaz A","year":"2016","unstructured":"Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sj\u00f6gren's syndrome. Rheum Dis Clin North Am. 2016, 42:419-34. 10.1016\/j.rdc.2016.03.002","journal-title":"Rheum Dis Clin North Am"},{"key":"ref10","article-title":"The meaning of anti-Ro and anti-La antibodies in primary Sj\u00f6gren\u2019s syndrome","volume":"10","author":"Hern\u00e1ndez-Molina G","year":"20111","unstructured":"Hern\u00e1ndez-Molina G, Leal-Alegre G, Michel-Peregrina M. The meaning of anti-Ro and anti-La antibodies in primary Sj\u00f6gren\u2019s syndrome. Autoimmun Rev. 20111, 10:123-5.","journal-title":"Autoimmun Rev"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231802","article-title":"Primary Sjogren's syndrome: a great masquerader","volume":"12","author":"Kumar N","year":"2019","unstructured":"Kumar N, Surendran D, Srinivas BH, Bammigatti C. Primary Sjogren's syndrome: a great masquerader. BMJ Case Rep. 2019, 12:10.1136\/bcr-2019-231802","journal-title":"BMJ Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1191\/096120300678828550","article-title":"Central pontine myelinolysis--a rare manifestation of CNS Sjogren's syndrome","volume":"9","author":"Yoon KH","year":"2000","unstructured":"Yoon KH, Fong KY, Koh DR, Suri R. Central pontine myelinolysis--a rare manifestation of CNS Sjogren's syndrome. Lupus. 2000, 9:471-3. 10.1191\/096120300678828550","journal-title":"Lupus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19644","article-title":"Rare case of central pontine myelinolysis: etiological dilemma","volume":"13","author":"Maturu MV","year":"2021","unstructured":"Maturu MV, Datla AV, Selvadasan V, Dalai S. Rare case of central pontine myelinolysis: etiological dilemma. Cureus. 2021, 13:e19644. 10.7759\/cureus.19644","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12847","article-title":"Central pontine myelinolysis in Sjogren's syndrome with hypokalemia","volume":"20","author":"Abdulla MC","year":"2017","unstructured":"Abdulla MC, Alungal J, Ahammed S, Narayan R. Central pontine myelinolysis in Sjogren's syndrome with hypokalemia. Int J Rheum Dis. 2017, 20:2168-70. 10.1111\/1756-185X.12847","journal-title":"Int J Rheum Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski CH","year":"2017","unstructured":"Shiboski CH, Shiboski SC, Seror R, et al.. 2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren's syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017, 69:35-45. 10.1002\/art.39859","journal-title":"Arthritis Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731122","article-title":"Rituximab therapy for primary Sj\u00f6gren's syndrome","volume":"12","author":"Chen YH","year":"2021","unstructured":"Chen YH, Wang XY, Jin X, Yang Z, Xu J. Rituximab therapy for primary Sj\u00f6gren's syndrome. Front Pharmacol. 2021, 12:731122. 10.3389\/fphar.2021.731122","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/art.21260","article-title":"Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study","volume":"52","author":"Pijpe J","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FK, et al.. Rituximab treatment in patients with primary Sj\u00f6gren's syndrome: an open-label phase II study. Arthritis Rheum. 2005, 52:2740-50. 10.1002\/art.21260","journal-title":"Arthritis Rheum"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25597","article-title":"Rituximab treatment of myasthenia gravis: a systematic review","volume":"56","author":"Tandan R","year":"2017","unstructured":"Tandan R, Hehir MK 2nd, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: a systematic review. Muscle Nerve. 2017, 56:185-96. 10.1002\/mus.25597","journal-title":"Muscle Nerve"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer JM","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A, et al.. Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010, 62:960-8. 10.1002\/art.27314","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals M","year":"2020","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S, et al.. EULAR recommendations for the management of Sj\u00f6gren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020, 79:3-18. 10.1136\/annrheumdis-2019-216114","journal-title":"Ann Rheum Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/336718-primary-sjogrens-disease-coexisting-with-myasthenia-gravis-two-distinct-autoimmune-diseases-successfully-treated-with-a-rituximab-based-induction-regimen","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T01:53:33Z","timestamp":1737942813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/336718-primary-sjogrens-disease-coexisting-with-myasthenia-gravis-two-distinct-autoimmune-diseases-successfully-treated-with-a-rituximab-based-induction-regimen"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.78018","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}